Hmmm.
What I recall him saying was that compounding pharmacies only get authorized to make this when there's a shortage, but the main pharmacies (Eli/Novartis? can't recall) claim there is no shortage but only offer one dosage, whereas he believes dosage should start with the bare minimum, and the be adjusted/tailored to the individual.
He also said combining GLPs with muscle sparing compounds like IGF1 (again ?) showed no muscle loss.  Also spoke about pharma trying to lobby against peptides on one hand, while trying to get patents on them on the other.
You disagree with all this?
First part is true, second claim is not at least up here. There are multiple dosage pens and the folks I have on it we always start with .25mgs (ozempic if most often covered, mounjaro only for the beetus) and sometimes I even suggest using click counting to start lower if there is some gastroparesis already etc.
The data on glp's and sarcopenia for the most part and in large (although the recent one on heart shrinkage was an outlier) indicate that the muscle loss is on par with other weight loss interventions- sleeve surgery etc- the speed of weight loss will determine the amount of sarcopenia. This can largely be mitigated with resistance training though. There doesn't appear to be any muscle wasting aspect of the drug. If you look at sema in comp to tirz, where tirz has GIP action, it upregulates hormone sensitive lipase and you see a skew towards more fat loss than muscle which makes sense if there isn't a sarcopenic aspect. Reta prob is muscle sparing as the recent study showed exogenous ketone addition spared muscle, and the glucagon agonism of that drug increase hepatic ketone production which should spare muscle. 
I dont know anything about the lobbying. I do know a lot of other peptides are awesome for similar issues- weight loss, insulin sens etc like mots-c- it even inhibits myostatin downstream.
Things are probably different in the states but I don't see up here.